Literature DB >> 17503891

Switch from risperidone to perospirone in patients with chronic schizophrenia.

Kazuyuki Fujita1, Toshihiko Fukuchi, Shoji Yuasa, Eriko Inada, Yoko Tarao, Kousuke Kanemoto.   

Abstract

Entities:  

Year:  2004        PMID： 17503891     DOI： 10.2165/00044011-200424050-00006

Source DB:  PubMed          Journal:  Clin Drug Investig        ISSN： 1173-2563            Impact factor:   2.859


× No keyword cloud information.
  9 in total

1.  Atypical antipsychotic medications and the treatment of schizophrenia.

Authors:  David A Lewis
Journal:  Am J Psychiatry       Date:  2002-02       Impact factor: 18.112

2.  Clozapine, olanzapine, risperidone, and haloperidol in the treatment of patients with chronic schizophrenia and schizoaffective disorder.

Authors:  Jan Volavka; Pal Czobor; Brian Sheitman; Jean-Pierre Lindenmayer; Leslie Citrome; Joseph P McEvoy; Thomas B Cooper; Miranda Chakos; Jeffrey A Lieberman
Journal:  Am J Psychiatry       Date:  2002-02       Impact factor: 18.112

3.  A comparison of risperidone and haloperidol for the prevention of relapse in patients with schizophrenia.

Authors:  John G Csernansky; Ramy Mahmoud; Ronald Brenner
Journal:  N Engl J Med       Date:  2002-01-03       Impact factor: 91.245

4.  The D2 dopamine receptor occupancy of risperidone and its relationship to extrapyramidal symptoms: a PET study.

Authors:  S Kapur; G Remington; R B Zipursky; A A Wilson; S Houle
Journal:  Life Sci       Date:  1995       Impact factor: 5.037

5.  Extrapyramidal symptom profiles in Japanese patients with schizophrenia treated with olanzapine or haloperidol.

Authors:  Toshiya Inada; Gohei Yagi; Sadanori Miura
Journal:  Schizophr Res       Date:  2002-10-01       Impact factor: 4.939

6.  In vitro receptor binding and in vivo receptor occupancy in rat and guinea pig brain: risperidone compared with antipsychotics hitherto used.

Authors:  A Schotte; P Bonaventure; P F Janssen; J E Leysen
Journal:  Jpn J Pharmacol       Date:  1995-12

Review 7.  The evolution of the serotonin-dopamine antagonist concept.

Authors:  M Huttunen
Journal:  J Clin Psychopharmacol       Date:  1995-02       Impact factor: 3.153

8.  Positron emission tomography studies on D2 and 5-HT2 receptor binding in risperidone-treated schizophrenic patients.

Authors:  L Farde; S Nyberg; G Oxenstierna; Y Nakashima; C Halldin; B Ericsson
Journal:  J Clin Psychopharmacol       Date:  1995-02       Impact factor: 3.153

9.  Pharmacological actions of SM-9018, a new neuroleptic drug with both potent 5-hydroxytryptamine2 and dopamine2 antagonistic actions.

Authors:  A Hirose; T Kato; Y Ohno; H Shimizu; H Tanaka; M Nakamura; J Katsube
Journal:  Jpn J Pharmacol       Date:  1990-07
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.